Heat-processed Panax ginseng and diabetic renal damage: active components and action mechanism

Ki Sung Kang1*, Jungyeob Ham1, Young-Joo Kim1, Jeong Hill Park2, Eun-Ju Cho3, and Noriko Yamabe3*

1Natural Medicine Center, Korea Institute of Science and Technology, Gangneung 210-340, Korea
2Research Institute of Pharmaceutical Sciences and College of Pharmacy, Seoul National University, Seoul 151-742, Korea
3Department of Food Science and Nutrition & Kimchi Research Institute, Pusan National University, Busan 609-735, Korea

Diabetic nephropathy is one of the serious complications in patients with either type 1 or 2 diabetes mellitus but current treatments remain unsatisfactory. Results of clinical research studies demonstrate that Panax ginseng can help adjust blood pressure and reduce blood sugar and may be advantageous in the treatment of tuberculosis and kidney damage in people with diabetes. The heat-processing method to strengthen the efficacy of P. ginseng has been well-defined based on a long history of ethnopharmacological evidence. The protective effects of P. ginseng on pathological conditions and renal damage associated with diabetic nephropathy in the animal models were markedly improved by heat-processing. The concentrations of less-polar ginsenosides (20(S)-Rg3, 20(R)-Rg3, Rg5, and Rk1) and maltol in P. ginseng were significantly increased in a heat-processing temperature-dependent manner. Based on researches in animal models of diabetes, ginsenoside 20(S)-Rg3 and maltol were evaluated to have therapeutic potential against diabetic renal damage. These effects were achieved through the inhibition of inflammatory pathway activated by oxidative stress and advanced glycation endproducts. These findings indicate that ginsenoside 20(S)-Rg3 and maltol are important bioactive constituents of heat-processed ginseng in the control of pathological conditions associated with diabetic nephropathy.

Keywords: Panax ginseng, Heat-processing, 20(S)-Rg3, Advanced glycation endproducts, Free radical

INTRODUCTION

The kidney is an excretory organ that plays a vital role in excretion of waste through urine in the human body. Diabetic nephropathy is an important cause of end-stage renal disease and is clinically defined as progressively increasing proteinuria accompanied by hypertension and impairment of glomerular filtration [1,2]. The onset of renal disease is multifactorial, involving oxidative stress, hypertension, hyperglycemia and hyperlipidemia [3-6]. The pathophysiological mechanisms that lead to nephropathy and the morphological features of diabetic renal damage are similar in type 1 and type 2 diabetes mellitus [2,7]. Under hyperglycemic condition, glucose and other reactive carbonyl compounds react non-enzymatically with proteins, lipids, or nucleic acids to form Schiff bases and Amadori products. Additional rearrangement and modification lead to the generation of diverse advanced glycation endproducts (AGEs), which can alter the structure and function of intra- and extracellular molecules, increase oxidative stress, and modulate cell activation,
signal transduction, and the expression of cytokines and growth factors through receptor-dependent and receptor-independent pathways [8-11]. In people with diabetes and/or chronic renal failure, AGEs that accumulate in the kidney are responsible for the pathological changes, including increased kidney weight, glomerular hypertrophy, glomerular basement membrane thickening, and progressive albuminuria [12].

Moreover, AGEs stimulate free radical mechanisms and induce membrane peroxidation, which in turn increase membrane permeability [11]. Therefore, AGE accumulation in the kidney has been regarded as an index of progressive renal damage in diabetic nephropathy. Reciprocally, oxidative stress is known to induce AGEs. Protein kinase C and mitogen-activated protein kinase-extracellular signal regulated kinases 1, 2 can be activated by reactive oxygen species (ROS) and signal profibrotic responses in kidney cells [13-15]. Several researchers have demonstrated that ROS generation induced by nicotinamide adenine dinucleotide phosphate oxidase and the mitochondrial electron-transport chain is an early event in the development of diabetic renal disease [1,16,17]. Therefore, a variety of synthetic antioxidants for reducing oxidative damage from generating free radicals and improving oxidative stress via improvement of the antioxidant activating system in the body in order to prevent or treat renal diseases have been proposed [10,13].

Clinical evidence has suggested that an appropriate use of traditional medicines in combination with modern Western medicine, or mainstream anti-diabetic drugs, can prevent or ameliorate the development of diabetic complications. Many diabetic patients choose alternative therapeutic approaches, such as herbal or traditional Chinese medicine along with the mainstream anti-diabetic drugs; thus, making alternative therapy for diabetes a popular remedy option [18]. Based on a large number of chemical and pharmacological research work, numerous bioactive compounds have been found in medicinal plants for diabetes [19]. Among the frequently mentioned herbal medicines that help manage blood glucose, ginseng extracts made from the root, rootlet, berry and leaf of Panax ginseng (Korean ginseng) and P. quinquefolius (American ginseng), have been proven effective for anti-hyperglycemia, insulin sensitization, islet protection, anti-obesity and anti-oxidation in many model systems [20].

EFFICACY OF CONVENTIONAL GINSENG AND GINSENOSIDES ON RENAL DAMAGE

P. ginseng is a perennial plant that belongs to the Panax species, Araliaceae family. Examples of Panax species plants having similar efficacy to P. ginseng include P. quinquefolius, P. notoginseng, P. japonica, P. trifolia, P. pseudoginseng, and P. vietnamensis. These Panax species plants contain dammarane-based saponin in common with 1 to 4 saccharide(s) combined with a dammarane backbone, unlike the other plants [21-23].

| Ginsenoside | Animal model | Mechanism | Reference |
|-------------|--------------|-----------|-----------|
| Rg1         | Spontaneously hypertensive rat | Repair of glomerular structure | 26 |
| UO          | Renal interstitial fibrosis ↓ | 25 |
| Re          | STZ-induced diabetic rat | Oxidative stress ↓ | 27 |
| Rb1         | Glycerol-induced acute renal failure | Renal function ↑ | 28 |
| UO          | Oxidative stress ↓ | 30 |
| Intestinal ischemia reperfusion-induced renal injury | Repair of renal morphology | 29 |
| Rd          | Renal function ↑ | 31-33 |
| Cisplatin-induced acute renal failure | Oxidative stress ↓ |
| Cephaloridine-induced renal failure | Nrf2/ARE pathway ↑ |
| Renal ischemia-reperfusion | |

UO, unilateral ureteral obstruction; VEGF, vascular endothelial growth factor; STZ, streptozotocin; Nrf2, nuclear factor erythroid 2-related factor 2; ARE, antioxidant response element.
In particular, ginseng that contains high concentration of saponins includes ginsenosides Rb1, Rb2, Rc, Rd, Rg1, and Re. These saponins have a variety of pharmaceutical effects that greatly differ in types and intensities, depending on the structures [21].

Alcoholic extract of *P. quinquefolius*, which shows presence of the major ginsenoside Rg1, Re, Rb1, Rc, Rb2, and Rd with predominance of the ginsenoside Rb1 and Re, was effective in the prevention of diabetic nephropathy through a combination of mechanisms, such as anti-hyperglycemic and antioxidant effects [24].

Table 1 shows potential approaches of conventional ginsenosides to prevent chemical, surgical and/or genetic-induced renal damage. Ginsenoside Rg1 (20 to 50 mg/kg) attenuated kidney damage with improvement on glomerular structure in spontaneously hypertensive rats and inhibited renal interstitial fibrosis in rats with unilateral ureteral obstruction, via suppressing oxidative stress [25,26]. Treatment of ginsenoside Re (20 mg/kg) restored the levels of both glutathione and malondialdehyde in the kidney of streptozotocin (STZ)-induced diabetic rats [27]. Ginsenoside Rb1 (25 to 60 mg/kg) ameliorated renal dysfunction in glycerol-induced acute renal failure in rats [28] and attenuated acute renal injury induced by ischemia-reperfusion by activating the Nrf2/ARE pathway [29]. Ginsenoside Rb1 (12.5 to 50 mg/kg) also inhibited renal interstitial fibrosis in rats with unilateral ureteral obstruction by modulating thrombospondin-1 and vascular endothelial growth factor expression [30]. Ginsenoside Rd (5 mg/kg) attenuated renal dysfunction by preventing oxidative stress in cisplatin or cephaloridine-induced acute renal failure and ischemic-reperfused rats [31-33]. Although the efficacy on nephropathy are poorly understood, total saponins of *P. notoginseng* has been tested on chronic renal failure (non-uremic) patients and showed good therapeutic results as improving the renal function and lowering urinary protein [34]. In addition, *P. ginseng* supplementation maintained good glycemic control and improved plasma glucose and insulin regulation safely beyond usual therapy in well-controlled type 2 diabetes [35].

**EFFICACY OF LESS-POLAR GINSENOSIDES ON FREE RADICAL AND RENAL DAMAGE**

Research in efforts to develop methods for increasing the pharmaceutical effect of ginseng by conversion of the dammarane-based saponin by high temperature and high pressure thermal processing has been conducted. The heat-processing method to strengthen the efficacy of ginseng has been well defined in Korea, based on the long history of ethnopharmacological evidence [21,23]. *P. ginseng* cultivated in Korea is harvested after 4 to 6 years of cultivation, and it is classified into three types depending on how it is processed. Fresh ginseng can be consumed in an unprocessed state. White ginseng (harvested when 4 to 6 years old) is dried ginseng root. Red ginseng is ginseng root steamed at 98°C to 100°C after peeling (Fig. 1) [22]. Red ginseng is more widely used than white ginseng in Asian countries, because steaming induces changes in the chemical constituents and enhances the biological activities of ginseng [22,36,37]. A novel heat-processing method of autoclaving ginseng at a higher temperature than red ginseng was recently developed to achieve an even stronger activity than that of red ginseng; this ginseng product was termed sun ginseng (SG) (Fig. 1) [38].

In vivo evidence for the roles of free radicals and AGEs in diabetic kidney disease comes mainly from studies in STZ-induced type 1 diabetic rats [11]. We have previously showed that the protective effects of both *P. ginseng* and *P. quinquefolius* on renal damages in STZ-induced diabetic rats were significantly improved by heat-processing [39,40]. The kidney protecting active components of heat-processed *P. ginseng* were identified by investigating further the changes in the constituents of *P. ginseng* by heat-processing and its antioxidant activity...
As a representative example, protopanaxadiol-type ginsenoside Rb1 and Rb2 are known to produce stereoisomers 20(S)-Rg3 and 20(R)-Rg3 by dissociation of a glycosyl residue located at carbon 20 by thermal processing, as illustrated in Fig. 2; followed by a dehydration reaction at carbon 20 to produce ginsenoside Rg5 and Rk1 [45,52]. Among them, 20(S)-Rg3 showed the strongest hydroxyl radical (•OH)-scavenging activity, and the following were shown in decreasing order; Rg5, 20(R)-Rg3, and Rk1 at a concentration of 0.5% [45].

According to the studies in STZ diabetic rats, the elevated serum glucose, glycosylated protein, and thiobarbituric acid-reactive substance levels in diabetic rats were significantly reduced by the 20(S)-Rg3 administrations (20 mg/kg) in STZ-induced diabetic rats [49]. In addition, the renal dysfunction of diabetic rats was significantly ameliorated by the 20(S)-Rg3 administrations in a dose-dependent manner. A growing body of evidence supports the important roles of renal N-methyl-d-aspartate (NMDA) receptors, originally identified in the central nervous system, in renal blood flow and nephrotoxicity. Moreover, the nephrotoxicity and renal vasoconstriction were attenuated by treatment with an NMDA receptor antagonist [54,55]. The elevated NMDA-NR1 levels of
diabetic rats were significantly decreased in the groups administered 20(S)-Rg3 or aminoguanidine (20 mg/kg body weight/d). These beneficial effects on diabetic renal damage were related to the inhibitory effect of 20(S)-Rg3 against NMDA receptor-mediated nephrotoxicity [49].

The sign of early diabetic nephropathy is an increased urinary albumin level, and advanced diabetic nephropathy is characterized by proteinuria and decreasing CCr levels [11]. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is an animal model of spontaneously obese type 2 diabetes characterized by hyperglycemia, insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypercholesterolemia, and with complications such as nonalcoholic fatty liver and renal disorders; in addition, these typical characteristics of OLETF rats are known to be useful for analyzing the complex forms of human diabetes (Fig. 3) [56,57]. In our previous study to identify the effect of 20(S)-Rg3 at advanced-stage of diabetic renal damage in OLETF rats, the elevation of pro-inflammatory protein expressions, such as inducible nitric oxide synthase and 3-nitrotyrosine were significantly reduced by the administrations of 20(S)-Rg3.

**EFFICACY OF MAL TOL ON AGES, FREE RADICLAS AND RENAL DAMAGE**

Although the main pharmacologically active constituents of ginseng are believed to be ginsenosides, researchers also have paid attention to the other components. It is well known that Maillard reaction products (MRPs) produced in both heat-treated food systems and in sugar-amino acid model systems have antioxidant activity [63-65]. MRPs in ginseng were reported to increase by heat-processing; these compounds are arginyl-fructosyl-glucose, arginyl-fructose, maltol, maltol-3-O-β-D-glucoside, and so on [66,67]. Maltol is formed by sucrose pyrolysis or thermal degradation of starch [68,69], and is extensively used in food, beverage, tobacco, brewery, cosmetics and pharmaceuticals industries [70]. When ginseng extracts were analyzed with GC-MS, content of maltol in red ginseng and SG was about 4 and 36 times higher, respectively, than in white ginseng [41,50]. There are several lines of evidence regarding the antioxidant
activities of maltol, and antioxidants are known to protect against glycation-derived free radicals and may have a therapeutic potential [8,61]. Maltol with hydroxypyrone structure acts as a potent metal-chelating agent [71], and complexes of maltol with metals are now applied to the treatment for some diseases [72-74].

Numerous AGE inhibitors have been investigated by in vitro AGE-inhibitory activity tests, but some classes of AGEs inhibition is primarily mediated by their transition metal-chelating or antioxidant activities [75,76]. In our previous in vitro study, maltol exhibited a stronger inhibitory effect against glucose-induced AGE generation than aminoguanidine, a well-known AGE inhibitor. In addition, the •OH scavenging activity of maltol was slightly stronger than that of aminoguanidine, and this effect was interpreted to be important because •OH scavenging activity in electron spin resonance spectrometer is mediated by the transition metal-chelating and free radical scavenging activities of the compounds [77].

In STZ-diabetic rats, maltol (50 mg/kg body weight/d) significantly decreased the renal fluorescent AGE level, suggesting that it would inhibit oxidative damage and irreversible renal damage caused by protein glycation reaction under diabetes [78]. In addition, the elevated CML expression, a major AGE in human tissues, and receptor for AGE levels in diabetic control rats were significantly reduced by the 50 mg/kg body weight/d of maltol administration. These findings imply that the beneficial effect of maltol in type 1 diabetic rats was mainly mediated by the inhibition of AGE generation (Table 2) [78].

**CONCLUSION AND PERSPECTIVES**

Diabetic nephropathy has been the major cause of patients needing chronic haemodialysis since 1998 [79,80]. Prevention of the occurrence and progression of diabetic nephropathy has become a very important issue. Results of clinical research studies demonstrate that *P. ginseng* can help adjust blood pressure and reduce blood sugar and may be advantageous in the treatment of tuberculosis and kidney damage in people with type 2 diabetes [34,35]. In this mini-review, we have summarized that the contents of free radical-scavenging active components, such as 20(S)-Rg3 and maltol in *P. ginseng* were significantly increased, depending on the temperature of heat-processing. Based on the observations on the roles of 20(S)-Rg3 and maltol in AGEs and free radicals in vitro and in vivo studies (type 1 and/or 2 diabetes models), 20(S)-Rg3 and maltol were evaluated to have therapeutic potential against diabetic renal damage in the early-stage. The identification and management of diabetic kidney disease in the early-stage is important because the majority of people have no symptoms until the disease is very advanced [81]. Therefore, the beneficial effects of ginsenoside 20(S)-Rg3 and maltol in the early-stage have important implication by preventing the advancement of diabetic renal damage to advanced-stages. Considering the relevant use and individual daily consumption of ginseng, it is clear that 20(S)-Rg3 and maltol are important bioactive constituents of heat-processed ginseng, especially in the control of diabetic renal complication. This investigation of bioactive constituents of heat-processed *P. ginseng* is important for the scientific elucidation of improved efficacies of ginseng by traditional and modern heat-processing methods, and may contribute to the development of ginseng-derived novel drugs.

**ACKNOWLEDGEMENTS**

This paper was studied with the support of the Ministry of Education Science and Technology and The Korean Federation of Science and Technology Societies. This work was also supported by the Korea Institute of Science and Technology institutional program (2Z03840).

---

**Table 2. Effect and mechanism action of heat-processed components in *Panax ginseng* on renal damage**

| Ginsenoside     | Animal model                                 | Mechanism                        | Reference |
|-----------------|----------------------------------------------|----------------------------------|-----------|
| 20(S)-Rg3       | STZ-induced diabetic rat                      | Renal function↑                  | 49        |
|                 |                                               | NM­DA-mediated nephrotoxicity↓    |           |
|                 | Otsuka Long-Evans Tokushima Fatty rat         | Renal function↑                  | 62        |
|                 |                                               | Oxidative stress↓                |           |
|                 |                                               | Advanced glycation endproduct↓   |           |
|                 | Lipopolysaccharide-induced renal injury       | Renal function↑                  | 48        |
|                 |                                               | Oxidative stress↓                |           |
|                 |                                               | Renal inflammation↓              |           |
| Maltol          | STZ-induced diabetic rat                      | Advanced glycation endproduct↓   | 78        |
|                 |                                               | Oxidative stress↓                |           |

STZ, streptozotocin; NM­DA, N-methyl-d-aspartate receptor.
REFERENCES

1. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003;14(Suppl 3):S221-S226.

2. Alsaaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007;60:18-26.

3. Sarafidis PA, Rulopez LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006;26:232-244.

4. Njoroge FG, Monnier VM. The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 1989;304:85-107.

5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.

6. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 2006;116:1756-1760.

7. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001;60:2041-2055.

8. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.

9. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Rama-samy R, Arnold B, Navrroth PP, Yan SF, D’Agati V et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383-1395.

10. Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003;41(3 Suppl 1):S42-S47.

11. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971-1010.

12. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Stef-fes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994;91:11704-11708.

13. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.

14. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-1972.

15. Tuttle KR, Johnson EC, Cooney SK, Anderberg RJ, Johnson BK, Clifton GD, Meek RL. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int 2005;67:953-968.

16. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003;419:63-79.

17. Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliveira-Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007;583(Pt 1):9-24.

18. Ceylan-Isik AF, Fliethman RM, Wold LE, Ren J. Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus. Curr Diabet Res 2008;4:320-328.

19. Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004;92:1-21.

20. Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111.

21. Park JH, Kim JM, Han SB, Kim NY, Surh YJ, Lee SK, Kim ND, Park MK. A new processed ginseng with fortified activity. In: Hur H, Choi KJ, Kim YC, eds. Advances in ginseng research. Seoul: Korean Society of Ginseng, 1998. p. 146-159.

22. Yun TK. Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci 2001;16 Suppl:S3-S5.

23. Yokozawa T, Kang KS, Yamabe N, Kim HY. Therapeutic potential of heat-processed Panax ginseng with respect to oxidative tissue damage. Drug Discov Ther 2007;1:30-44.

24. Sen S, Chen S, Feng B, Wu Y, Lui E, Chakrabarti S. Preventive effects of North American ginseng (Panax quinquefolium) on diabetic nephropathy. Phytotherapy 2012;19:494-505.

25. Xie XS, Liu HC, Wang FP, Zhang CL, Zuo C, Deng Y, Fan JM. Ginsenoside Rg1 modulation on thrombospon-din-1 and vascular endothelial growth factor expression in early renal fibrogenesis in unilateral obstruction. Phytother Res 2010;24:1581-1587.

26. Chen H, Yin J, Deng Y, Yang M, Xu L, Teng F, Li D, Cheng Y, Liu S, Wang D et al. The protective effects of ginsenoside Rg1 against hypertension target-organ damage in spontaneously hypertensive rats. BMC Complement Altern Med 2012;12:53.

27. Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies
in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006;550:173-179.
28. Zhang HA, Wang M, Zhou J, Yao QY, Ma JM, Jiang CL. Protective effect of ginsenoside Rg1 against acute renal failure and expression of tyrosine hydroxylase in the locus coeruleus. Physiol Res 2010;59:61-70.
29. Sun Q, Meng QT, Jiang Y, Xia ZY. Ginsenoside Rb1 attenuates intestinal ischemia reperfusion induced renal injury by activating Nrf2/ARE pathway. Molecules 2012;17:7195-7205.
30. Xie XS, Liu HC, Yang M, Zhuo C, Deng Y, Fan JM. Ginsenoside Rb1, a panaxadiol saponin against oxidative damage and renal interstitial fibrosis in rats with unilateral ureteral obstruction. Chin J Integr Med 2009;15:133-140.
31. Yokozawa T, Liu ZW, Dong E. A study of ginsenoside-Rd in a renal ischemia-reperfusion model. Nephron 1998;78:201-206.
32. Yokozawa T, Owada S. Effect of ginsenoside-Rd in cephaloridine-induced renal disorder. Nephron 1999;81:200-207.
33. Yokozawa T, Liu ZW. The role of ginsenoside-Rd in cisplatin-induced acute renal failure. Ren Fail 2000;22:115-127.
34. Peng SL, Guo ZA. Effect of total saponins of Panax notoginseng on urinary albumin in patients with chronic renal failure. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2010;22:744-746.
35. Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Di Buono M, Lee KS, Leiter LA, Nam KY, Armaso JT et al. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis 2008;18:46-56.
36. Kasai R, Besso H, Tanaka O, Saruwatari YI, Fuwa T. Saponins of red ginseng. Chem Pharm Bull (Tokyo) 1983;31:2120-2125.
37. Matsuura H, Hirao Y, Yoshida S, Kunihiro K, Fuwa T, Kasai R, Tanaka O. Study of red ginseng: new glucosides and a note on the occurrence of maltol. Chem Pharm Bull (Tokyo) 1984;32:4674-4677.
38. Kim WY, Kim JM, Han SB, Lee SK, Kim ND, Park MK, Kim CK, Park JH. Steaming of ginseng at high temperature enhances biological activity. J Nat Prod 2000;63:1702-1704.
39. Kim HY, Kang KS, Yamabe N, Nagai R, Yokozawa T. Protective effect of heat-processed American ginseng against diabetic renal damage in rats. J Agric Food Chem 2007;55:8491-8497.
40. Kim HY, Kang KS, Yamabe N, Yokozawa T. Comparison of the effects of Korean ginseng and heat-processed Korean ginseng on diabetic oxidative stress. Am J Chin Med 2008;36:989-1004.
41. Kang KS, Kim HY, Pyo JS, Yokozawa T. Increase in the free radical scavenging activity of ginseng by heat-processing. Biol Pharm Bull 2006;29:750-754.
42. Kang KS, Yokozawa T, Kim HY, Park JH. Study on the nitric oxide scavenging effects of ginseng and its compounds. J Agric Food Chem 2006;54:2558-2562.
43. Kang KS, Kim HY, Yamabe N, Yokozawa T. Stereospecificity in hydroxyl radical scavenging activities of four ginsenosides produced by heat processing. Bioorg Med Chem Lett 2006;16:5028-5031.
44. Kang KS, Kim HY, Yamabe N, Nagai R, Yokozawa T. Protective effect of sun ginseng against diabetic renal damage. Biol Pharm Bull 2006;29:1678-1684.
45. Kang KS, Kim HY, Back SH, Yoo HH, Park JH, Yokozawa T. Study on the hydroxyl radical scavenging activity changes of ginseng and ginsenoside-Rb2 by heat processing. Biol Pharm Bull 2007;30:724-728.
46. Kang KS, Yokozawa T, Yamabe N, Kim HY, Park JH. ESR study on the structure and hydroxyl radical-scavenging activity relationships of ginsenosides isolated from Panax ginseng C A Meyer. Bio Pharm Bull 2007;30:917-921.
47. Kang KS, Lee YJ, Park JH, Yokozawa T. The effects of glycine and L-arginine on heat stability of ginsenoside Rb1. Biol Pharm Bull 2007;30:1975-1978.
48. Kang KS, Kim HY, Yamabe N, Park JH, Yokozawa T. Preventive effect of 20(S)-ginsenoside Rg3 against lipopolysaccharide-induced hepatic and renal injury in rats. Free Radic Res 2007;41:1181-1188.
49. Kang KS, Yamabe N, Kim HY, Park JH, Yokozawa T. Therapeutic potential of 20(S)-ginsenoside Rg3(3) against streptozotocin-induced diabetic renal damage in rats. Eur J Pharmacol 2008;591:266-272.
50. Kang KS, Tanaka T, Cho EJ, Yokozawa T. Evaluation of the peroxynitrite scavenging activity of heat-processed ginseng. J Med Food 2009;12:124-130.
51. Yamabe N, Song KI, Lee W, Han IH, Lee JH, Ham J, Kim SN, Park JH, Kang KS. Chemical and free radical-scavenging activity changes of ginsenoside Rb1 by Maillard reaction and its possible use as a renoprotective agent. J Ginseng Res 2012;36:256-262.
52. Lee YJ, Kim HY, Kang KS, Lee JG, Yokozawa T, Park JH. The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing. Bioorg Med Chem Lett 2008;18:4515-4520.
53. Yamabe N, Lee JG, Lee YJ, Park CH, Kim HY, Park JH, Yokozawa T, Kang KS. The chemical and 1,1-diphenyl-
2-pierylhydrazyl radical scavenging activity changes of ginsenosides Rb1 and Rg1 by Maillard reaction. J Ginseng Res 2011;35:60-68.

54. Deng A, Valdivielso JM, Munger KA, Blantz RC, Thomson SC. Vasodilatory N-methyl-D-aspartate receptors are constitutively expressed in rat kidney. J Am Soc Nephrol 2002;13:1381-1384.

55. Leung JC, Marphis T, Craver RD, Silverstein DM. Altered NMDA receptor expression in renal toxicity: protection with a receptor antagonist. Kidney Int 2004;66:167-176.

56. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.

57. Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008;23:102-109.

58. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.

59. Nagai R, Unno Y, Hayashi MC, Masuda S, Hayase F, Kinai N, Horiuchi S. Peroxynitrite induces formation of N(epsilon)-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glycine and glyoxy- mal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes 2002;51:2833-2839.

60. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897.

61. Ahmed N. Advanced glycation endproducts: role in pathology of diabetic complications. Diabetes Res Clin Pract 2005;67:3-21.

62. Kang KS, Yamabe N, Kim HY, Park JH, Yokozawa T. Effects of heat-processed ginseng and its active component ginsenoside 20(S)-Rg3 on the progression of renal damage and dysfunction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty rats. Biol Pharm Bull 2010;33:1077-1081.

63. Wijewickreme AN, Krejciro Z, Kitts DD. Hydroxyl scavenging activity of glucose, fructose, and ribose-lysine model Maillard products. J Food Sci 1999;64:457-461.

64. Bekedam EK, Schols HA, Cammerer B, Kroh LW, van Boekel MA, Smit G. Electron spin resonance (ESR) studies on the formation of roasting-induced antioxidative structures in coffee brews at different degrees of roast. J Agric Food Chem 2008;56:4597-4604.

65. Chen XM, Kitts DD. Antioxidant activity and chemical properties of crude and fractionated Maillard reaction products derived from four sugar-amino acid Maillard reaction model systems. Ann NY Acad Sci 2008;1126:220-224.

66. Li X, Zheng Y, Liu M, Zhang L. A study on maillard reaction and its products during processing of red ginseng. Zhongguo Zhong Yao Za Zhi 1999;24:274-278.

67. Suzuki Y, Choi KJ, Uchida K, Ko SR, Solhn HJ, Park JD. Arginyl-fructosyl-glucose and arginyl-fructose, compounds related to browning reaction in the model system of steaming and heat-drying processes for the preparation of red ginseng. J Ginseng Res 2004;28:143-148.

68. Johnson RR, Alford ED, Kinzer GW. Formation of sucrose pyrolysis products. J Agric Food Chem 1969;17:22-24.

69. Ito H. The formation of maltol and isomaltol through degradation of sucrose. Agric Biol Chem 1977;41:1307-1308.

70. Bjeldanes LF, Chen H. Mutagenicity of 1,2-dicarbonyl compounds: maltol, kojic acid, diacetyl and related substances. Mutat Res 1979;67:367-371.

71. Yasumoto E, Nakano K, Nakayachi T, Morshed SR, Hashimoto K, Kikuchi H, Nishikawa H, Kawase M, Sakagami H. Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Anticancer Res 2004;24:755-762.

72. Harvey RS, Reffitt DM, Doig LA, Meenan J, Ellis RD, Thompson RP, Powell JJ. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 1998;12:845-848.

73. Verma S, Cam MC, McNeill JH. Nutritional factors that can favorably influence the glucose/insulin system: vanadium. J Am Coll Nutr 1998;17:11-18.

74. Reffitt DM, Burden TJ, Seed PT, Wood J, Thompson RP, Powell JJ. Assessment of iron absorption from ferric trimaltol. Ann Clin Biochem 2000;37(Pt 4):457-466.

75. Jang DS, Kim JM, Lee YM, Kim YS, Kim JH, Kim JS. Puerariafuran, a new inhibitor of advanced glycation end products (AGEs) isolated from the roots of Pueraria lobata. Chem Pharm Bull (Tokyo) 2006;54:1315-1317.

76. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001;276:48967-48972.

77. Huang D, Ou B, Prior RL. The chemistry behind antioxidative capacity assays. J Agric Food Chem 2005;53:1841-
1856.
78. Kang KS, Yamabe N, Kim HY, Yokozawa T. Role of maltol in advanced glycation end products and free radicals: in-vitro and in-vivo studies. J Pharm Pharmacol 2008;60:445-452.
79. Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T, Yamazaki C, Sakai R, Ohmori H, Morita O et al. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004;8:3-32.
80. Yamabe N, Yokozawa T. Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima fatty rat: a model of human type 2 diabetes mellitus. J Pharm Pharmacol 2006;58:535-545.
81. Levin A. Identification of patients and risk factors in chronic kidney disease: evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16 Suppl 7:57-60.